Outcomes in 45 Patients With Statin-Associated Myopathy
Abstract
Background Published studies regarding statin-associated myopathy may describe more dramatic patient presentations, potentially leading to inaccurate characterization of the condition. Furthermore, long-term outcomes and responses to statin rechallenge in patients with statin-associated myopathy are largely unknown. Methods The University of Wisconsin Hospital and Clinics Medical Informatics Department identified 437 patients with International Classification of Diseases, Ninth Revision codes potentially representing cases of statin-associated myopathy from more than 13 years of inpatient and outpatient data; 45 of these individuals were diagnosed as having statin-associated myopathy. Using a standardized form, 2 researchers abstracted all the case records to define the clinical course of statin-induced myopathy. Results The mean (SD) duration of statin therapy before symptom onset was 6.3 (9.8) months. Resolution of muscle pain occurred a mean (SD) of 2.3 (3.0) months after discontinuation of statin therapy. Six patients (13%) were hospitalized for the management of rhabdomyolysis; 2 had reversible renal dysfunction, and 1 with preexisting renal insufficiency subsequently began lifelong dialysis. Hospitalized patients developed myopathy more quickly after initiating statin therapy (1.3 vs 7.1 months; P = .048) and were more likely to be taking concomitant medications known to increase the risk of statin-associated myopathy (P = .03). Thirty-seven patients received another st…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Observational studies have found that statin-related symptoms can take several months to resolve.
“and again several months for them to resolve [24–26].”
From Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [24]
Observational studies have found that statin-related symptoms can take several months to develop.
“observational studies have found it can take several months for statin-related symptoms to develop”
From Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [24]
SAMS usually occur 4-6 weeks after statin introduction and can last for up weeks to months after statin therapy discontinuation.
“SAMS usually occur 4–6 weeks after statin introduction and can last for up weeks to months after statin therapy discontinuation [14,54].”
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · see citing works
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463 · see citing works
A novel anti-inflammatory role for simvastatin in inflammatory arthritis.
Leung, B. P., Sattar, N., Crilly, A., Prach, M., McCarey, D. W., Payne, H., Madhok, R., Campbell, C., Gracie, J. A., Liew, F. Y., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1524 · Cited by 434 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Discontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548 · see citing works
Acid-suppressive medication use and the risk for hospital-acquired pneumonia
Herzig, S. J. (2009) · JAMA · doi:10.1001/jama.2009.722 · Cited by 486 · see citing works
Narrative review: statin-related myopathy
Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453 · see citing works
Statin-Associated Autoimmune Myopathy
Mammen, A. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515161 · Cited by 366 · see citing works
Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00006 · Cited by 275 · see citing works
Phenotype standardization for statin-induced myotoxicity
Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Carr, D. F., Bloch, K. M., Fahy, J., Hanson, A., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.121 · Cited by 220 · see citing works
Ahmad, Z. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.02.033 · Cited by 110 · see citing works
Statin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102 · see citing works
Nutraceuticals for the treatment of hypercholesterolemia
Mannarino, M. R., Ministrini, S., & Pirro, M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.06.008 · Cited by 92 · see citing works
Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy
Keating, A. J., Campbell, K. B., & Guyton, J. R. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r509 · Cited by 74 · see citing works
Moriarty, P. M., Roth, E. M., Karns, A., Ye, P., Zhao, S.-P., Liao, Y., Capuzzi, D. M., Bays, H. E., Zhang, F., Liu, S., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.002 · Cited by 65 · see citing works
Clinical characterization and molecular mechanisms of statin myopathy
Toth, P. P., Harper, C. R., & Jacobson, T. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.955 · Cited by 55 · see citing works
EXPRESSION OF CONCERN: Mitophagy protects against statin‐mediated skeletal muscle toxicity
Ramesh, I., Campos, J. C., Lee, P., Song, Y., Hernandez, G., Sin, J., Tucker, K. C., Saadaeijahromi, H., Gurney, M., Ferreira, J. C. B., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900807rr · Cited by 17 · see citing works
Kraut, R., Wierenga, F., Molstad, E., Korownyk, C., Perry, D., Dennett, L., & Garrison, S. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295857 · Cited by 7 · see citing works
Aebi, P. S., Villoz, F., Bührer, J., Lyko, C., Abolhassani, N., Del Giovane, C., Gencer, B., Rodondi, N., & Blum, M. R. (2025) · PLOS One · doi:10.1371/journal.pone.0338575
“SAMS usually occur 4–6 weeks after statin introduction and can last for up weeks to months after statin therapy discontinuation [14,54].”
- Authors
- Hansen, K. E., Hildebrand, J. P., Ferguson, E. E., & Stein, J. H.
- Affiliations
- University of Wisconsin–Madison (US)
- ORCID
- Stein, James H.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2005-12-12
- Volume
- 165
- Issue
- 22
- Pages
- 2671
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2160936671
- Cited by
- 280
- References
- 3
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 12 · 2022: 16 · 2021: 20 · 2020: 13 · 2019: 11 · 2018: 8 · 2017: 13 · 2016: 21 · 2015: 12 · 2014: 19 · 2013: 22 · 2012: 11
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR050995)
- National Center for Research Resources (K12RR017614, K23 RR16176-01, K23RR016176)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- statin-induced myopathy, rhabdomyolysis, statin rechallenge, myalgia, long-term outcomes, drug discontinuation, concomitant medications, renal dysfunction, dialysis, hospitalization
- MeSH terms
- Age Factors, Hypolipidemic Agents, Creatine Kinase, Drug Therapy, Combination, Female, Hospitalization, Humans, Male, Middle Aged, Muscular Diseases, Pain, Recurrence, Retrospective Studies, Rhabdomyolysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Recovery of Function, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
